Can I Take Alpha-Lipoic Acid with Vyvanse?

Updated Jul 14, 2025

Image: HealthRX.com clinical image

Lisdexamfetamine (brand name Vyvanse, an amphetamine-prodrug CNS stimulant approved for ADHD and moderate-to-severe binge eating disorder) has no known pharmacokinetic interaction with alpha-lipoic acid (ALA), a mitochondrial cofactor sold over the counter as a racemic or R-enantiomer supplement. ALA does not meaningfully inhibit or induce the enzymes that convert lisdexamfetamine to active d-amphetamine, so it will not raise or lower Vyvanse blood levels. The relevant concern is pharmacodynamic: both agents can independently lower blood glucose or influence appetite and metabolism, and the combination has not been studied together in a controlled trial, so the size of any additive effect in a given person is not established.

At a glance

Drug / lisdexamfetamine (Vyvanse), FDA-approved oral capsule, typically 20 to 70 mg once daily
Supplement / alpha-lipoic acid (ALA), an over-the-counter antioxidant supplement, not FDA-regulated as a drug
Interaction type / pharmacodynamic (overlapping glucose-lowering and metabolic effects), not a pharmacokinetic drug-level interaction
Primary concern / additive hypoglycemia-like symptoms such as shakiness, light-headedness, or difficulty concentrating, particularly if meals are irregular
Secondary concern / high-dose ALA (reported above roughly 600 mg/day in some studies) has been associated with modest reductions in free T4 in limited research
Direct trial evidence for this specific combination / none identified
Who needs extra caution / people with diabetes on glucose-lowering medication, thyroid disease, or binge eating disorder with irregular eating patterns
Verdict / generally manageable with basic precautions and disclosure to a prescriber; not a reason to avoid ALA outright for most healthy adults

What Vyvanse Does in the Body

Vyvanse is a prodrug. After ingestion, it is converted enzymatically to l-lysine and d-amphetamine, and the d-amphetamine produces the clinical effect. The FDA approved lisdexamfetamine for ADHD in 2007 and later for moderate-to-severe binge eating disorder, according to the current FDA-approved prescribing information.

D-amphetamine increases synaptic norepinephrine and dopamine, and stimulation of hypothalamic pathways involved in appetite regulation is part of how the drug reduces food intake. In the binge eating disorder trials that supported FDA approval, lisdexamfetamine reduced binge eating frequency and was associated with weight loss compared with placebo; exact percentage figures from those trials are not reproduced here because the original trial citation could not be independently verified for this draft, and a precise number should not be presented without confirming it against the primary trial report or the FDA label's efficacy summary.

This appetite-suppressing effect matters for the ALA question because reduced food intake, especially skipped or delayed meals, is itself a risk factor for low blood sugar symptoms, independent of anything ALA does.

What Alpha-Lipoic Acid Does in the Body

Alpha-lipoic acid is a naturally occurring compound that acts as a cofactor for mitochondrial enzyme complexes involved in energy metabolism. As a supplement it is sold as a racemic mixture or as the R-enantiomer alone, with R-ALA generally considered more bioavailable per milligram.

ALA is most studied for diabetic peripheral neuropathy, where intravenous and oral formulations have shown modest symptom improvement in clinical trials. A plausible, biologically supported mechanism for its blood-glucose effect is activation of AMP-activated protein kinase (AMPK) and increased translocation of GLUT4 glucose transporters in skeletal muscle, which would increase glucose uptake independent of insulin. Small trials in people with type 2 diabetes have reported reductions in fasting glucose with oral ALA, though the exact magnitude reported varies across studies and should be confirmed against the specific trial before being cited as a fixed number.

Separately, some older and smaller studies have reported that high-dose ALA can interfere with thyroid hormone conversion or binding, potentially lowering circulating free T4. This body of evidence is thinner than the glucose-lowering literature, includes animal data, and has not been confirmed in large human trials. It should be treated as plausible but not established in humans at typical supplement doses.

The Interaction: What Is Actually Known Versus Assumed

No published trial has enrolled people taking both lisdexamfetamine and alpha-lipoic acid to measure glucose, thyroid, or safety outcomes directly. Everything below is inference from two separate literatures, not a direct study of the combination.

Glucose-lowering overlap

Vyvanse reduces appetite and food intake. ALA is proposed to increase insulin-independent glucose uptake through AMPK activation. These are different mechanisms converging on the same physiological output: lower circulating glucose or lower glucose availability relative to demand. This is a pharmacodynamic overlap, not a drug-level interaction, and it does not require a change in Vyvanse dosing to occur, since it does not depend on blood concentration of either substance being altered by the other.

People using insulin or sulfonylureas face the most direct risk, because a third glucose-lowering mechanism is added on top of medications already designed to lower glucose. People with type 1 diabetes should treat any new supplement with glucose-lowering potential as something to discuss with their diabetes care team before starting, given that hypoglycemia in insulin users is a genuine medical event, not just a nuisance symptom.

Thyroid axis overlap

Stimulants like Vyvanse can modestly increase metabolic rate through norepinephrine signaling, though this is not the same mechanism proposed for ALA's effect on thyroid hormone. If a person already has thyroid disease, or takes levothyroxine or liothyronine, checking in with the prescribing clinician before adding high-dose ALA is a reasonable precaution, mainly because free T4 monitoring is inexpensive and the biological plausibility of an effect exists, even though it is not firmly established in humans at typical supplement doses.

What is not a concern here

ALA does not appear to meaningfully affect the CYP enzymes involved in amphetamine metabolism, and lisdexamfetamine's conversion to active drug happens through enzymatic hydrolysis rather than pH-dependent absorption, so a classic pharmacokinetic drug interaction (one substance changing the blood level of the other) is unlikely. This is a reassuring point for people mainly worried about ALA making Vyvanse "stronger" or "weaker."

Evidence-Status Interaction Assessment

Use this table to see which parts of the Vyvanse-ALA discussion rest on solid ground versus inference, and what a prescriber or pharmacist should verify before treating any specific claim as settled.

Claim	Evidence status	What supports it	What a clinician should verify
ALA does not alter Vyvanse blood levels via CYP metabolism	Established, low uncertainty	General pharmacology of amphetamine metabolism and lack of known ALA CYP inhibition	Confirm no new interaction data have emerged since publication of this page
Vyvanse suppresses appetite and can reduce meal frequency	FDA-labeled effect	FDA-approved prescribing information	Individual variation in appetite suppression by dose and indication
ALA increases insulin-independent glucose uptake (AMPK/GLUT4 mechanism)	Plausible, supported by mechanistic and small clinical studies	Diabetes-focused ALA trials; mechanism is well described in the ALA literature generally	The specific magnitude of glucose lowering at a given ALA dose in a non-diabetic person
Combining Vyvanse and ALA produces additive (not synergistic) hypoglycemia-like symptoms in most people	Not directly studied; a reasonable clinical inference	Separate literatures on each agent's glucose effect	Whether the person has other glucose-lowering exposures (insulin, sulfonylureas, alcohol, low-carbohydrate diet)
High-dose ALA reduces free T4 by a specific percentage	Not established in humans with confidence	Limited studies, some in animals; human data are sparse	The original study population, dose, and whether findings replicate in humans before quoting any percentage
This exact combination has been studied in a randomized trial	Not established	No such trial identified	Search current literature and clinicaltrials.gov before assuming this remains true
FAERS shows no distinct safety signal for this combination	Not established as reassuring evidence	FAERS is a passive reporting system	FAERS under-reports supplement-drug interactions; absence of signal is not evidence of safety

Who Should Be More Careful

People with type 1 or type 2 diabetes, especially those using insulin or sulfonylureas, should treat ALA as a supplement with real glucose-lowering potential and loop in their prescriber before adding it. People with diagnosed thyroid disease, particularly those on thyroid hormone replacement, have a plausible reason to check thyroid labs before and after starting high-dose ALA. People taking Vyvanse specifically for binge eating disorder often have irregular eating patterns already, and adding a second glucose-lowering variable without medical input is a reasonable thing to avoid.

Healthy adults without diabetes or thyroid disease who are taking Vyvanse for ADHD and considering ALA at typical over-the-counter doses face a lower level of concern, though "lower" is not the same as "zero," since neither agent's individual effect size at those doses guarantees a negligible combined effect in every person.

Practical Timing and Monitoring

Vyvanse is generally taken once in the morning. Because both agents can influence glucose within a similar window after dosing, spacing ALA a few hours apart from the morning Vyvanse dose and taking it with food is a reasonable, low-cost precaution, even though no trial has established that spacing meaningfully changes outcomes for this specific pair.

People taking both agents regularly, especially anyone in a higher-risk group above, may want to discuss with their clinician whether checking fasting glucose and, if on high-dose ALA, free T4, makes sense at baseline and again after a few weeks. This is a judgment call based on individual risk factors rather than a guideline-mandated protocol, since no specialty guideline currently addresses this specific supplement-drug pair.

When to Contact a Prescriber or Seek Urgent Care

Reach out to a prescriber or pharmacist before starting ALA if diabetes, thyroid disease, or binge eating disorder with irregular meals is part of the picture, or if other glucose-lowering supplements or medications (such as chromium, cinnamon extract, berberine, metformin, insulin, or sulfonylureas) are already in use.

Seek urgent medical care for symptoms of significant hypoglycemia, such as confusion, slurred speech, seizure, or loss of consciousness, rather than waiting for a routine appointment. Milder symptoms such as shakiness, irritability before meals, or new light-headedness are worth reporting at the next visit but are not typically an emergency on their own. Vyvanse should not be stopped abruptly without prescriber guidance, consistent with standard stimulant discontinuation practice described in the FDA prescribing information.

What Remains Uncertain

Established: Vyvanse causes appetite suppression through its FDA-labeled mechanism, and ALA has a biologically plausible glucose-lowering mechanism supported by studies in diabetic populations. Neither agent is known to alter the other's blood concentration through a classic pharmacokinetic interaction.

Plausible but unproven: that combining the two produces a clinically meaningful additive glucose-lowering or hypoglycemia-like effect in a typical, non-diabetic adult, and that high-dose ALA meaningfully lowers free T4 in humans at supplement-relevant doses.

Not established: any trial-based estimate of how often or how severely this specific combination causes symptoms, and any confirmed pharmacovigilance signal linking the two.

Frequently asked questions

Can I take alpha-lipoic acid while on Vyvanse?

For most healthy adults without diabetes or thyroid disease, taking ALA at typical over-the-counter doses alongside Vyvanse is not considered contraindicated. The main concern is that both can lower blood glucose through separate mechanisms, which may cause dizziness or shakiness if meals are skipped. This combination has not been studied directly in a clinical trial, so the guidance is based on inference from separate evidence, not a head-to-head study.

Does alpha-lipoic acid interact with Vyvanse?

The interaction is pharmacodynamic rather than pharmacokinetic. ALA has a proposed glucose-lowering mechanism through AMPK activation, and Vyvanse suppresses appetite and food intake. Together they may produce additive effects on blood glucose or glucose-related symptoms. ALA does not appear to inhibit or induce the enzymes that metabolize amphetamine, so it should not change Vyvanse blood levels directly.

Is alpha-lipoic acid safe with Vyvanse?

It is generally considered manageable with basic precautions, but safety depends on individual health status. People with diabetes, thyroid disease, or binge eating disorder with irregular meals face more uncertainty and should discuss the combination with a prescriber first. Healthy adults at standard ALA doses face a lower level of concern but should still watch for hypoglycemia-like symptoms.

Can ALA make Vyvanse stronger or weaker?

ALA does not appear to meaningfully alter Vyvanse blood levels, because it does not significantly affect the enzymes involved in lisdexamfetamine's conversion to active drug or in amphetamine metabolism generally. The interaction concern is about overlapping physiological effects, not a change in drug concentration.

Can alpha-lipoic acid cause low blood sugar with Vyvanse?

It may contribute to hypoglycemia-like symptoms, particularly for people who skip meals, since Vyvanse already suppresses appetite and ALA has an independent glucose-lowering mechanism. True clinical hypoglycemia, a glucose level low enough to require treatment, is more of a concern for people already using insulin or sulfonylureas than for people without diabetes.

Does ALA affect thyroid function when taken with Vyvanse?

High-dose ALA has been linked to reduced free T4 in limited studies, some conducted in animals, and human evidence at typical supplement doses is thin. Vyvanse itself is not known to directly alter thyroid hormone levels. Anyone with existing thyroid disease considering high-dose ALA should discuss baseline and follow-up thyroid labs with their clinician rather than relying on a fixed percentage effect.

Should I take ALA and Vyvanse at the same time?

Taking Vyvanse in the morning and spacing ALA a few hours later, with food, is a reasonable precaution given the overlapping glucose-related windows, though this exact timing strategy has not been tested in a trial for this specific pair.

What symptoms should I watch for if I combine ALA and Vyvanse?

Shakiness, cold sweats, difficulty concentrating, unusual irritability, or light-headedness, especially in the hours after both are taken, are worth noting. Unexplained weight loss beyond what would be expected from Vyvanse alone is also worth reporting to a prescriber.

Do I need to tell my doctor I am taking ALA with Vyvanse?

Yes. Telling a prescriber or pharmacist about any supplement with a plausible effect on blood glucose or thyroid function allows them to decide whether monitoring makes sense for your specific health history.

Can I take ALA with Vyvanse if I have binge eating disorder?

Extra caution is reasonable. Vyvanse is FDA-approved for binge eating disorder, and people with this condition often have irregular meal patterns that already affect blood glucose regulation. Adding a supplement with a proposed glucose-lowering effect without input from the treating clinician or eating disorder care team is not advisable.

References

U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard